Premium
A Phase II study of paclitaxel by 24‐hour infusion and ifosfamide in anthracycline‐resistant metastatic breast carcinoma
Author(s) -
Seo Jae H.,
Whang Young M.,
Kim Byung S.,
Choi Chul W.,
Shin Sang W.,
Kim Yeul H.,
Kim Jun S.,
Goo Bum H.
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10431
Subject(s) - medicine , ifosfamide , mucositis , mesna , chemotherapy , anthracycline , metastatic breast cancer , epirubicin , regimen , gastroenterology , surgery , cyclophosphamide , breast cancer , urology , cancer , etoposide
BACKGROUND A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline‐resistant metastatic breast carcinoma (MBC). METHODS Recurrent or progressed MBC within 12 months after anthracycline‐based chemotherapy was defined as anthracycline‐resistant. A 24‐hour infusion of paclitaxel (175 mg/m 2 ) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m 2 /day) with mesna (360 mg/m 2 /day) on Days 2– 4, were performed every 3 weeks. Twenty‐one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5‐fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. RESULTS Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2–24+) and 19+ months (range, 2–32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony‐stimulating factor. Other significant toxicities were peripheral neuropathy ( n = 3), mucositis ( n = 2), and liver dysfunction ( n = 1). However, there was no chemotherapy‐related death. CONCLUSIONS Paclitaxel by 24‐hour infusion combined with ifosfamide is efficacious in the treatment of anthracycline‐resistant MBC with tolerable toxicity. Further trials verifying the result of the authors' study are warranted. Cancer 2002;94:1925–30. © 2002 American Cancer Society. DOI 10.1002/cncr.10431